Structures reveal details of small molecule binding to cardiac troponin

Fangze Cai a, Monica X. Li b, Sandra E. Pineda-Sanabria a, Shorena Gelozi c, Steffen Lindert d, Frederick West e, Brian D. Sykes a, Peter M. Hwang a,b,⁎

a Department of Biochemistry, University of Alberta, Edmonton, AB, Canada
b Department of Medicine, University of Alberta, Edmonton, AB, Canada
c Department of Chemistry, University of Alberta, Edmonton, AB, Canada
d Department of Chemistry and Biochemistry, Ohio State University, Columbus, OH, USA

A R T I C L E   I N F O

Article history:
Received 9 August 2016
Received in revised form 22 October 2016
Accepted 25 October 2016
Available online 5 November 2016

Keywords:
Nuclear magnetic resonance spectroscopy
Drug development
Cardiac troponin activator
Calcium sensitizer
Systolic heart failure

A B S T R A C T

In cardiac and skeletal muscle, the troponin complex turns muscle contraction on and off in a calcium-dependent manner. Many small molecules are known to bind to the troponin complex to modulate its calcium binding affinity, and this may be useful in a broad range of conditions in which striated muscle function is compromised, such as congestive heart failure. As a tool for developing drugs specific for the cardiac isoform of troponin, we have designed a chimeric construct (cChimera) consisting of the regulatory N-terminal domain of cardiac troponin C (cNTnC) fused to the switch region of cardiac troponin I (cTnI), mimicking the key binding event that turns on muscle contraction. We demonstrate by solution NMR spectroscopy that cChimera faithfully reproduces the native interface between cTnI and cNTnC.

We determined that small molecules based on diphenylamine can bind to cChimera with a Kd as low as 10 μM. Solution NMR structures show that minimal structural perturbations in cChimera are needed to accommodate 3-methyldiphenylamine (3-mDPA), which is probably why it binds with higher affinity than previously studied compounds like bepridil, despite its significantly smaller size. The unsubstituted aromatic ring of 3-mDPA binds to an inner hydrophobic pocket adjacent to the central beta sheet of cNTnC. However, the methyl-substituted ring is able to bind in two different orientations, either inserting into the cNTnC-cTnI interface or “flipping out” to form contacts primarily with helix C of cNTnC. Our work suggests that preservation of the native interaction between cNTnC and cTnI is key to the development of a high affinity cardiac troponin-specific drug.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Cardiovascular disease is the number one cause of death worldwide [1], and heart failure is the end stage of almost all heart disease. Heart failure occurs when the heart is unable to pump sufficient blood to satisfy the needs of the body. Impaired cardiac muscle contraction results in systolic heart failure, also referred to as heart failure with reduced ejection fraction (HFrEF). By far, the most common cause of HFrEF is ischemic cardiomyopathy. However, in the absence of atherosclerotic coronary disease or valvular abnormalities, a wide range of etiologies encompassing infiltrative, infectious, autoimmune, toxic, hormonal, and genetic causes, can give rise to dilated cardiomyopathy (DCM) [2]. Over time, the volume overload that develops in HFrEF causes the heart muscle to further dilate, thin, and scar, making it even more difficult to generate force.

Positive inotropes, which increase the contractility of heart muscle to enhance cardiac output, should theoretically be useful in the treatment of systolic heart failure. Two inotropes used in acute decompensated heart failure are dobutamine and milrinone, both of which up-regulate sympathetic β1-adrenergic stimulated pathways to increases heart rate and stroke volume [3]. However, inotropes acting on these pathways increase the oxygen demand of the heart and further increase mortality by precipitating life-threatening arrhythmias and systemic hypotension. A different class of positive inotropes is the calcium sensitizers, which increase the contractile response of the heart to calcium, in contrast to calcium mobilizers like dobutamine and milrinone. The first calcium sensitizer to reach large-scale clinical trials is levsimendan [4]. It was found to increase cardiac output without increasing oxygen demand [5]. Earlier trials showed improved survival in the treatment of acute decompensated systolic heart failure, but larger phase III trials did not show a mortality benefit [6,7].

Levsimendan and its active metabolite, OR-1896, bind to cardiac troponin (cTn) [8,9], the protein switch that turns contraction on and off in a calcium-dependent manner. The heterotrimeric Ctn complex is composed of the calcium-binding subunit troponin C (cTnC), the inhibitory subunit troponin I (cTnI), and the tropomyosin-binding subunit troponin T (cTnT) [10]. Under resting calcium concentrations, the tropo-nin complex maintains tropomyosin in a position that blocks actin–

⁎ Corresponding author at: Department of Medicine, University of Alberta, Edmonton, AB, Canada.
E-mail address: phwang1@ualberta.ca (P.M. Hwang).

http://dx.doi.org/10.1016/j.yjmcc.2016.10.016
0022-2828/© 2016 Elsevier Ltd. All rights reserved.
Calcium sensitizing drugs.

While intracellular calcium concentration increases, calcium binding to the N-terminal regulatory domain of cTnC (cNTnC) induces binding of the switch region of cTnI (residues 147–163) [12]. This in turn promotes the dissociation of the cTnI inhibitory region (residues 135–147) from actin, shifting tropomyosin to expose the myosin-binding sites on actin and allowing cardiac contraction to proceed. Since cNTnC is the calcium-dependent switch for contraction and relaxation in cardiac muscle, it is a prime target for developing calcium sensitizing drugs.

While levosimendan has been shown to bind to cNTnC [13, 14], it has been shown to impact the activity of other proteins as well, including type 3 phosphodiesterase [15] and ATP-sensitive potassium channels [16, 17]. It is possible that off-target binding could potentially give rise to unintended adverse effects, like hypotension. We aim to develop calcium sensitizers that are more specific for cardiac troponin.

In the current study, we demonstrate that compounds based on the small molecule diphenylamine are able to bind to cardiac troponin with reasonably high affinity (K_D 10 μM) given their small size. Our solution NMR structures reveal how one of these compounds, 3-methyl diphenylamine, binds to a deep but narrow hydrophobic cavity in the troponin C-1 complex. Optimizing the fit to this tight cavity will be essential to developing high affinity cardiac troponin-modulating compounds.

2. Material and methods

2.1. cChimera design, expression, and purification

Hybrid proteins have been used to simplify systems with complex protein–protein interactions [19, 20], including both skeletal and cardiac muscle isoforms of troponin [21, 22]. Since dfbp-o and other compounds are known to bind to the interface between NtC and TnI switch peptide [23], we developed a cardiac troponin C-troponin I chimera, cChimera, in which the switch region of cTnI is fused to the C terminus of cNTnC, building upon the previous design cNTnC-linker-switch peptide 144–173 [21]. cChimera begins with residues 1 to 90 of human cNTnC (C35S, C84S), followed by residues 136–163 of cTnI (comprising the inhibitory region and switch 147–163 regions) and ending with a C-terminal Gly and His-tag (see Fig. 1). The inhibitory region acts as linker between cNTnC and the cTnI switch region, and residues 136 and 137 of the cTnI inhibitory region are coincidentally the same as residues 91 and 92 of cNTnC. Unlike the previous chimera, in which the engineered linker region contains a protease cleavage site [21], all of the amino acids residues in our new cNTnC-cTnI chimera are derived from the native cNTnC or cTnI sequence, with the exception of the C-terminal Gly and His-tag. Our new 125-aminoc acid 14.2 kDa cChimera construct has the following advantages over the previous construct [21]: native N-terminus of cTnC, switch region of cTnI extended N-terminally to include the inhibitory region (residues 136–147), which also serves as the linker to cNTnC, C35S and C84S double mutation to avoid issues with cysteine oxidation, and shortened C-terminal tail of cTnI, limiting the number of disordered residues contributing to NMR spectral overlap.

The expression plasmid for the cChimera was produced by DNA 2.0, with a high copy number origin of replication, ampicillin selection, and IPTG-inducible T5 RNA polymerase (which uses native Escherichia coli RNA polymerase) promoter. Isotope-enriched [15N, 13C]-cNTnC-cTnI chimera were expressed in E. coli BL21(DE3) as previously described [24]. The expression of cChimera was carried out in 1 L of minimal M9 medium, containing 9 g Na2HPO4 and 2.5 g KH2PO4 at pH 7.3–7.4. To the autoclaved phosphate solution was added a filtered, sterilized solution containing 1 mL of 1 M MgSO4, 1 mL of 100 mM CaCl2, 1 mg of biotin, 200 mg of thiamine, 1 g [15N] NH4SO4 (99.9 atom %), 3 g [13C] glucose (99.0 atom %) dissolved in 20 mL ddH2O, and 1 mL of 10% ampicillin. Cells from a 2 L culture were grown to a cell density between 400 0.7 and 1.0 and then induced for 6 h with 1 mM IPTG. Cells were harvested by centrifugation at 5000 rpm (4420 × g) for 15 min and then resuspended in 20 mL buffer containing 50 mM Tris (pH 8.0), 10 mM MgSO4, 10 μg/mL DNase and 1 mM CaCl2. Cells were lysed by adding 20 mg of lysozyme and 200 mg of deoxycholic acid, with mechanical homogenization to break cell clumps. The cell lysate was clarified by centrifugation at 15,000 rpm (27,200 × g) and then syringe-filtered using a 0.8 μm filter. The supernatant was applied to a Ni-NTA column equilibrated with binding buffer (20 mM Tris–HCl, 0.3 M NaCl, 10 mM imidazole, 1 mM CaCl2), washed with the same buffer containing 80 mM imidazole, and then eluted with the same buffer with 250 mM imidazole. Purified fractions were dialyzed against 5 mM ammonium bicarbonate and 10 mM CaCl2 for three days and then lyophilized. Protein identity and purity >95% were confirmed by gel electrophoresis and mass spectrometry. Yield was ~60–100 mg purified protein per liter of growth culture.

Fig. 2. a) The eight lowest energy solution NMR structures of cChimera (cTnI switch region shown in red). b) The x-ray structure cNTnC-cTnI derived from the cardiac troponin complex (1J1E.pdb, grey) was aligned by secondary structural elements (residues 3–85) to cChimera (cNTnC region: blue, cyan, green, and yellow spectrum, cTnI inhibitory region linker: orange, cTnI switch region: red). c) Residue Val146 of cTnI (red) forms contacts with Pro52, Glu56 and Met60 (green) of cNTnC, shown in sticks.
2.2 Chemicals

Bepridil (N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline) and 3-methyldiphenylamine (3-mDPA) were purchased from Sigma-Aldrich. 3-Chlorodiphenylamine was purchased from Toronto Research Chemicals Inc. All "NCI" compounds in the study were provided by the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI). All "Chembridge" compounds were provided by ChemBridge Corp. All "SHG" compounds were synthesized in-house (see Supplementary Materials section), with the identity and purity confirmed by NMR spectroscopy.

2.3 NMR spectroscopy

NMR samples contained 0.1–0.6 mM cChimera in 100 mM KCl, 10 mM imidazole buffer pH ~6.8, 5–10 mM CaCl₂, and 0.25 mM 2,2-dimethyl-2-silapentane-5-sulfonate-d₆ sodium salt (DSS-d₆) as an NMR internal reference in 95/5% H₂O/D₂O or 100% D₂O. Stock solutions of 10 to 50 mM of small compounds were prepared in DMSO-d₆ (Cambridge Isotopes Inc.) and added independently in aliquots to the protein sample. By the end of each titration, the addition of DMSO-d₆ did not exceed 10% of the sample volume. NMR data were acquired on a Varian Inova 500 MHz or 800 MHz spectrometer at 30 °C. Both spectrometers are equipped with triple resonance probes with pulsed field gradients.

2.3.1 Drug titrations

The binding of 3-methyl diphenylamine (3-mDPA) to cChimera was monitored using 2D-¹H,¹⁵N HSQC and 2D-¹H,¹³C HSQC NMR spectra. We titrated 0.15 mM ¹⁵N-cChimera with 0.01, 0.03, 0.06, 0.1, 0.2, 0.4 and 0.7 mM of 3-mDPA while acquiring 2D-¹H,¹⁵N HSQC spectrum. We titrated 0.25 mM ¹³C,¹⁵N-cChimera with 0.05, 0.1, 0.25, 0.5 and 0.8 mM of 3-mDPA while acquiring 2D-¹H,¹³C HSQC spectrum. The

![Fig. 3. Chemical structures and cChimera binding affinity (KD) of N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline (bepridil), benzylaniline, dibenzylamine, diphenylamine (DPA), 3-methyldiphenylamine (3-mDPA) and 3-chlorodiphenylamine (3-ClDPA). For bepridil, KD* is binding affinity to cTnC-switch cTnI peptide complex (binding to cChimera could not be accurately measured).](image)

![Fig. 4. a) Overlay of 2D HSQC spectra of cChimera acquired during titration with 3-mDPA. The first point of each titration is represented with multiple contours and subsequent titration points for the drug are represented by single contours. Residues that experienced large chemical shift changes are labeled. b) Global fit for residues in cChimera that experienced large chemical shift perturbations upon addition of 3-mDPA. KD ~ 30 μM.](image)
of drug compound precipitation during the titration, \( K_d \) would be underestimated because the observed chemical shift changes plateau early due to precipitation instead of protein saturation. Thus, the 3-point titration provides a lower bound estimate of \( K_d \). To provide an upper bound estimate for \( K_d \) for insoluble compounds, the last titration point was removed and replaced by chemical shifts corresponding to cChimera fully saturated with 3-chlorodiphenylamine, the compound with the highest affinity in this study, displaying some of the largest chemical shift changes. This seemed to be a reasonable approximation, given that the observed chemical shift change patterns were similar in all titrations of DPA-based compounds.

### 2.3.2. NMR experiments for structure calculation

The backbone \(^{1}H\), \(^{15}N\), and \(^{13}C\) chemical shift assignments for cChimera (both with and without 3-mDPA) were obtained by analyzing 3D CBCA(CO)NH, 3D HNCA(CB), 3D HN(CA)CO and 3D HNCO experiments. 3D (H)(C)(CO)NH-TOCSY (total correlation spectroscopy) and (H)(C)(CO)NH-TOCSY experiments were used to obtain side-chain \(^{1}H\) and \(^{13}C\) chemical shift assignments. Moreover, 3D HNHB and 3D HN(CO)HB experiments were used in combination with 3D \(^{15}N\)-edited NOESY (75 ms mixing time) to obtain stereospecific assignment for \( \beta \)-methylene protons and \( \gamma \), \( \delta \) dihedral angles. However, this strategy worked reliably only for residues with trans \( \chi_2 \) dihedral angle (\( \chi_2 \) and N at 180°) due to the low inherent sensitivity of the HN(CO)HB experiment, so that we were unable to distinguish between gauche+ and gauche− conformations. Stereospecific assignments of Val, Leu methyl groups were derived from 2D constant time \(^{1}H\), \(^{13}C\) HSQC of \(^{15}N\), 10% \(^{13}C\)-cChimera (pro-R methyl groups were in phase with alanine methyl groups) [25]. Aromatic side-chain resonances were assigned using an aromatic 3D \(^{13}C\)-edited NOESY-HSQC.

3D \(^{15}N\)-edited NOESY-HSQC (mixing time 75 ms), and 3D \(^{13}C\)-edited NOESY (mixing time 100 ms) were obtained to provide intramolecular (within the protein cChimera) distance restraints. 2D \(^{13}C\)-\(^{15}N\)-double-filtered NOESY (150 ms mixing time) experiments were obtained on 3-mDPA in complex with \(^{13}C\), \(^{15}N\)-labeled cChimera to obtain chemical shift assignments and intramolecular distance restraints for bound 3-mDPA. Intramolecular distance restraints between 3-mDPA and cChimera were derived from a 3D \(^{13}C\)-filtered/edited NOESY-HSQC (mixing times: 75 ms) experiment. Protons from the methyl-containing aromatic ring of 3-mDPA could not be observed (though the methyl group itself was observable), because of broadening of 3-mDPA resonances. These resonances could still be observed in the 3D \(^{13}C\)-edited NOESY-HSQC, due to the shorter pulse sequence employed.

---

**Fig. 5.** The backbone \(^{1}H\) and \(^{15}N\) chemical shift differences (\( \Delta \delta \)) between cChimera and cChimera-3-mDPA as a function of sequence.

**Fig. 6.** a) Overlay of 2D \(^{13}C\)-HSQC spectra of cChimera acquired during the titration of 3-mDPA. b. Global fit for residues in cChimera that experienced large chemical shift perturbations upon addition of 3-mDPA. \( K_d \approx 25 \mu M \).
Table 1
Total numbers of structural restraints used in the final round of ARIA calculations.

<table>
<thead>
<tr>
<th></th>
<th>cChimera</th>
<th>cChimera + 3-mDPA peptide</th>
<th>cChimera + 3-mDPA solvent exposed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Backbone dihedral angles</td>
<td>192</td>
<td>192</td>
<td>192</td>
</tr>
<tr>
<td>Sidechain dihedral angles</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Unambiguous distance restraints</td>
<td>1730</td>
<td>1630</td>
<td>1630</td>
</tr>
<tr>
<td>Ambiguous distance restraints</td>
<td>420</td>
<td>370</td>
<td>370</td>
</tr>
<tr>
<td>Intermolecular drug-protein distance restraints</td>
<td>–</td>
<td>30</td>
<td>30</td>
</tr>
</tbody>
</table>

Intermolecular restraints between 3-mDPA and cChimera could be easily identified in this unfiltered experiment (containing both intra- and intermolecular NOEs) by comparing the spectrum derived from cChimera bound to 3-mDPA with that from cChimera alone. This was the most sensitive method for obtaining intermolecular NOEs. VNMIR v.2.21B (Varian, Inc.) was used for the analysis of one-dimensional NMR spectra, and all 2D and 3D NMR data were processed with NMRPipe [26] and analyzed with NMRViewJ [27], using scripts written in-house.

2.4. Structure calculation

Backbone φ- and ψ-dihedral angle restraints were obtained using TALOS + [28], which makes predictions based on backbone chemical shifts (1Hα, 13Cα, 13Cβ, 15N, and 1HN). Restraints were used only for those residues for which there was complete agreement from all 10 nearest database hits with a chemical shift-derived backbone order parameter > 0.65 [29].

NOE-derived distance restraints for the cChimera protein were generated using ARIA 2.3 [30,31], using default settings. ARIA automatically generates distance restraints based on peak tables derived from NOESY spectra. Initially, most restraints are ambiguous due to chemical shift degeneracy. With each successive cycle of restrained molecular dynamics with simulated annealing using CNS 1.21 [32], generated structures are used to resolve ambiguities, and the proportion of unambiguous distance restraints increases with each cycle (eight in total). The frequency window tolerances for assigning NOEs were 0.02 and 0.03 ppm for direct and indirect proton dimensions, respectively, and 0.2 ppm for nitrogen and carbon dimensions. Fairly narrow tolerance ranges could be employed because the chemical shift assignments were adjusted to exactly match signals in the NOESY spectra. Dihedral angle restraints derived from TALOS + were incorporated in the calculation. We found that two spectral artifacts created problems for the ARIA program—diagonal peaks needed to be removed (as specified in the ARIA graphical user interface), and sinc wiggles also had to be manually removed from the NOESY peak lists. Moreover, in our experience, mobile regions of the protein would give rise to high intensity peaks that ARIA erroneously assigns to cause structural distortions if chemical shift assignments are not 100% complete. Thus, NOE cross-peaks involving unstructured regions of the protein were also removed from peak lists after manual inspection confirmed that there was no long range NOEs that could contribute to protein folding.

The web-based server, PRODRG [33], was used to generate topology and parameter files for 3-mDPA. Calcium was not included in the ARIA structure calculations, but 3-mDPA was included. Intermolecular NOEs between 3-mDPA and cChimera were not included in the peak lists. Instead, these NOE peaks were manually assigned and used to generate distance restraints that were added to the ARIA structure calculations. All intramolecular protein NOEs were calibrated automatically and assigned iteratively by ARIA; the final assignments were checked manually for errors. 80 conformers with lowest energy were calculated for each iteration; after the eighth iteration, 40 conformers with the lowest restraint energies were refined in a shell of water, and 8 conformers with the lowest total energies were selected.

2.5. Virtual screening of DPA-like compounds

DPA-like compounds (based on diphenylmethylene, diphenylether, and diphenylamine) were extracted from the NCI database. For this the NCI substructure search was used for SMILES strings c2ccc(Nc1ccccc1)cc2, c2ccc(Cc1cccccc1)cc2, and c2ccc(Oc1ccccc1)cc2. A total of 15,876 compounds were retrieved. These were prepared for docking using LigPrep with the protocol described previously [34]. This generated 23,438 compounds. The compounds were subsequently ordered by predicted docking score and ligand efficiency. Lastly, NCI compounds with every possible single substitution at the 3 (meta) position (based on diphenylmethylene, diphenylether, and diphenylamine) were identified using the NCI substructure search tool. A total of 61 compounds were identified which were again prepared for docking using LigPrep, generating a total of 72 compounds. After Glide XP docking, those 72 compounds were ranked by docking score. Compounds were selected for NMR binding studies if they scored well, were predicted to be soluble, had a molecular weight < 300 Da, and were available from NCI.

3. Results and discussion

3.1. Structure of cChimera

The NMR solution structure of the cTnC1–30–cTnI136–163 chimera (cChimera) was determined in the absence of any drug (Fig. 2a). As shown in Fig. 2b, the NMR structure of cChimera superimposes well with the corresponding regions in the X-ray crystal structure of the cardiac troponin complex (1J1E.pdb) [10], with a root-mean-square deviation (RMSD) of 1.2 Å for the backbone heavy atoms of residues 3–85 of cTnC. The linker region between cTnI and cTnC switch region is highly mobile by NMR, as indicated by random coil chemical shifts and lack of NOE contacts to the rest of the protein. Val146 is the first structured residue in cTnI immediately following the linker, showing NOEs to Pro52, Glu56 and Met60 of cTnC (Fig. 2c). This is the first time these contacts have been observed in an NMR structure, though they are also present in a single asymmetric unit of the crystal structure, showing that Val146 is actually part of the switch region of cTnI that binds to cTnC. The conformation and interactions of the rest of the switch region of cTnI are similar in the X-ray and NMR structures, with residues 146–149 in an extended conformation and residues 150–159 forming an alpha helix. Residues C-terminal to Leu159 are flexible according to the X-ray structure (different conformations observed within the asymmetric unit) and as indicated by NMR chemical shifts.

In many EF-hand proteins, calcium binding triggers a closed-to-open conformational transition [36]. However, in cTnC, the closed conformation predominates still upon calcium binding, though the open form is still populated to a small degree [37]. Binding of the cTnI 146–158 switch region locks cTnC into the open conformation, characterized by a rotation of the B—C helical unit away from helices N-A-D. The cTnI switch region binds to the outer C-terminus of helix B and helices A-D (Fig. 2a), analogous to wedging a wastebasket between a door and its frame to keep it open. Importantly, this leaves a sizeable cavity between the hinge of the protein (the central β sheet) and the cTnI peptide, where drug binding can occur. The size and configuration of this cavity is virtually identical between cChimera and the X-ray structure.

3.2. Selection of diphenylamine as starting compound

Bepridil is a calcium channel blocker that was previously marketed as a treatment for angina. As an off-target effect, it was previously
found to bind to the troponin complex to act as a calcium sensitizer [38]. A crystal structure showed that in the absence of cTnI, bepridil binds to the hydrophobic patch of cNTnC and stabilizes its calcium-bound open state, though its binding site overlaps with where the cTnI switch region normally binds [39]. NMR studies showed that bepridil and cTnI switch region bind to calcium-saturated cNTnC simultaneously but with negative cooperativity [40]. Thus, bepridil binding stabilizes the calcium-bound open state of cNTnC (with a K_D of 20 μM), but also destabilizes the complex by displacing the cTnI switch peptide. In the presence of switch peptide, bepridil binds with an affinity of 80 μM [40]. We tested the binding of bepridil to cChimera, but were unable to obtain a binding constant due to signal broadening, consistent with competitive binding of bepridil against the switch peptide. Since the binding affinity of bepridil for cNTnC was the highest of any compound published to date, we decided that it would be a good starting point for drug design.

In the NMR-based structure determination of bepridil bound to cNTnC-cTnI switch peptide, it was evident that most NOE-derived distance restraints localized to the two aromatic rings of bepridil. Of these, benzylaniline is a fragment of bepridil that binds with a K_D of 150 μM (Fig. 3). Removing the methylene carbon to yield diphenylamine (DPA) improved binding to K_D 120 μM, while addition of a methylene carbon (dibenzylamine) completely abolished binding. The effect of adding methylene carbons is at least two-fold, increasing the length of the molecule and increasing the partial positive charge on the central nitrogen atom (increasing pK_a), and both of these factors likely contribute to decreased binding to cChimera. While DPA bound to cChimera with slightly lower affinity than what was previously found for bepridil, we noted that the molecular weight of DPA was less than half that of bepridil, making it an excellent starting scaffold for drug development. We initially added single methyl or chloro substituents and found that 3-chlorodiphenylamine (3-ClDPA) was able to bind in two different orientations, two separate structures were pursued for each set. Since the two sets of NOEs indicated that 3-mDPA binds with its para-position (furthest from the central nitrogen) making it an excellent starting point for structure determination.

3.3. Interaction of cChimera with 3-mDPA

To characterize its interaction with cChimera, 3-mDPA was titrated into 15N-labeled cChimera and monitored by 1H, 13C HSQC NMR spectra (Fig. 4a). Backbone chemical shifts migrated in a linear fashion, indicating a 1:1 stoichiometry. Since 3-mDPA interacts with cChimera on a fast exchange timescale, almost all resonances could be easily followed throughout the titration. Chemical shift changes of the backbone amides of Phe27, Ser37, Ile61, Val64, Asp65, Glu66, Phe77, Val79, and Ala150 were plotted as a function of 3-mDPA-to-cChimera concentrations; a global dissociation constant (K_D) of 29 μM was determined (Fig. 4b). Chemical shift changes in cChimera upon titration with 3-mDPA are shown in Fig. 5. Chemical shift mapping of 1H and 13C signals do not seem to accurately delineate the small molecule binding site in cNTnC. Instead, they are sensitive markers of conformational changes in the protein [41] that are needed to accommodate drug binding. The largest 15N chemical shift changes are seen in Val64 and Met81 in cNTnC, and Ala150 in cTnI, highlighting hotspots of conformational change that occur upon 3-mDPA binding.

13C chemical shift changes upon 3-mDPA titration were also tracked using 1H, 13C HSQC NMR spectra. The chemical shift changes of the methyl groups of Ile61, Val64, Met80, and Met153 were plotted as a function of 3-mDPA-to-cChimera concentrations; a global dissociation constant (K_D) of 25 μM was determined (Fig. 6a and b). The largest chemical shift changes observed in methyl groups seems to map more consistently to the binding site than the backbone amide chemical shift changes.

3.4. Solution structure of the cChimera-3-mDPA complex

Accurate determination of the drug binding site of cChimera requires a complete solution structure determination of the protein-drug complex, complete with a full set of NOE-derived distance restraints and chemical shift-derived dihedral angle restraints (see Table 1). NOEs from the cChimera protein to the methyl substituted ring of 3-mDPA clustered into two groups, with one set of NOEs to a solvent-exposed site in cNTnC (to Met60 and Val64) and another set localizing to the cNTnC-cTnI interface (Val44, Met45, Leu48 of cNTnC and Ile148 and Met153 of cTnI). Both sets could not be simultaneously satisfied within a single structure. Since the two sets of NOEs indicated that 3-mDPA was able to bind in two different orientations, two separate structure calculations were performed for each set. Coincidently, both NOE distance restraint sets contained 30 out the 43 total 3-mDPA-cChimera intermolecular restraints (17 restraints common to both sets, 13 restraints unique to each set).

Unlike the methyl-substituted ring of 3-mDPA, NOEs to the unsubstituted aryl ring unambiguously position it into a deep pocket, with its para-position (furthest from the central nitrogen) making contacts with the central β-sheet core of cNTnC, centered about Ile36 and Val72 (Fig. 7a). This deep binding subsite must be sterically tight, since the presence of a single methyl group on the meta-substituted ring precludes binding in this location. The positioning of the deep binding site corresponds exactly to the binding site of the phenyl ring of bepridil in both the X-ray and NMR structures of the cNTnC-bepridil complex [39,40]. Remarkably, this deep binding pocket is present even
in the absence of small molecule binding, as seen in the structure of cChimera alone and in the X-ray structure of the cardiac troponin complex [10]. However, it is occupied by Met80, though its sidechain is too small to perfectly fill the cavity. We postulate that binding of any sizeable molecule to the central cavity of cNTnC requires displacement of the Met80 sidechain, making this the minimal conformational change necessary to support drug binding. Displacement of Met80 is achieved through sidechain $\chi$ dihedral angle rotations, with the backbone of Met80 relatively fixed within helix D (Fig. 7b). The linear nature of the methionine sidechain makes it the amino acid most able to adapt to a wide range of binding partners, a phenomenon that has been well characterized in calmodulin, a versatile signaling protein homologous to TnC that is able to interact with a plethora of protein targets through its methionine-rich binding surfaces [42]. The importance of Met80 sidechain displacement in cNTnC for drug binding is supported by the fact that NMR signal from the $\varepsilon$CH$_3$ group of Met80 moves and broadens more than any other $^1$H–$^{13}$C group in the $^1$H–$^{13}$C HSQC spectrum of cChimera as 3-mDPA is added (Fig. 6a). The conformational change of the Met80 sidechain likely accounts for the large chemical shift changes that occur in its vicinity upon drug binding, including the backbone $^{15}$N chemical shift of Met81 (Fig. 5).

In contrast to the unsubstituted aryl ring, NOEs observed for the methyl-substituted ring of 3-mDPA cluster into two distinct groups that can only be satisfied by two distinct modes of 3-mDPA binding (Fig. 8a). One set of NOEs localizes to the cNTnC-cTnI interface, with the methyl group of 3-mDPA nestled between residues Val44, Met45, and Leu48 in helix B, and the rest of the ring making contacts with Ile148, Ala150, and Met153 of the cTnI switch peptide. The ring is also spatially close to the sidechains of Met80 and Ser84, but intermolecular NOEs could not be observed due to exchange-induced signal broadening of these residues. The hydrophobic burial of the 3-mDPA methyl group explains its favorable effect on cChimera binding.

The sidechain of Ile148 is the most deeply inserted element of cTnI relative to the hydrophobic cavity of cNTnC (Fig. 8a). Although the sidechain does not extend deeply enough to fill the cavity, it does need to be displaced to allow insertion of the 3-mDPA methyl-substituted ring. Ile148 is a $\beta$-branched amino acid, and displacement of its sidechain by 3-mDPA requires a rotation of the extended backbone around Ile148 along its long axis (Fig. 8b). This accounts for the large changes in chemical shift that occur in this region upon titration with 3-mDPA (Fig. 5).

In the alternative mode of 3-mDPA binding to cChimera, the methyl-substituted ring is flipped out of the switch peptide interface into a solvent-exposed space adjacent to helix C, resulting in NOEs to Met60 and Val64 of helix C (Fig. 8a). Val64 is in an opposite corner of the drug binding site, spatially distant from the interface between cTnI switch peptide and cNTnC helix B. This solvent-exposed binding site corresponds well with the location of the pyrrolidine ring in the cNTnC-bepridil X-ray crystal structure (Fig. 8c). It has fewer hydrophobic contacts than the interface site, mainly Met60, Val64, and Met80, suggesting that binding here would not be as favorable. However, the intensity of NOEs to Met60 and Val64 suggest that this mode of binding is as favorable as

![Fig. 9](image-url)
Table 2

Binding affinity ($K_D$) of DPA-like compounds for cChimera. $K_D$ is the affinity constant calculated from small molecule titration, with the proviso that it provides a lower bound estimate (that is, a $K_D$ that is too low) when the compound precipitates out before the final point in the titration. $K_D^\ast$ is calculated based on the assumption that if solubility of the compound were not a limiting factor, saturation with the compound would cause chemical shift perturbations similar to 3-ClDPA. “Weak binding” denotes when titration with a compound led to very small chemical shift changes that could not be fit to a saturating curve, indicating a $K_D > 2$ mM.

<table>
<thead>
<tr>
<th>Compound</th>
<th>$K_D$</th>
<th>$K_D^\ast$</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-methyldiphenalamine</td>
<td>60 μM</td>
<td>120 μM</td>
</tr>
<tr>
<td>2-methyldiphenalamine</td>
<td>15 μM</td>
<td>25 μM</td>
</tr>
<tr>
<td>2,2′,5′-trimethyldiphenalamine</td>
<td>3 μM</td>
<td>30 μM</td>
</tr>
<tr>
<td>NSC215211</td>
<td>400 μM</td>
<td>800 μM</td>
</tr>
<tr>
<td>2-chlorodiphenylamine</td>
<td>10 μM</td>
<td></td>
</tr>
<tr>
<td>NSC50696</td>
<td>40 μM</td>
<td>30 μM</td>
</tr>
<tr>
<td>NSC59989</td>
<td>20 μM</td>
<td>10 μM</td>
</tr>
<tr>
<td>NSC11182</td>
<td>10 μM</td>
<td>10 μM</td>
</tr>
<tr>
<td>NSC17285</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSC167798</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSC3947</td>
<td>180 μM</td>
<td>90 μM</td>
</tr>
<tr>
<td>NSC167798</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weak binding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSC3947</td>
<td>180 μM</td>
<td>90 μM</td>
</tr>
<tr>
<td>Weak binding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-methyldiphenalamine</td>
<td>30 μM</td>
<td>50 μM</td>
</tr>
<tr>
<td>2,2′-3′-trimethyldiphenalamine</td>
<td>5 μM</td>
<td>100 μM</td>
</tr>
<tr>
<td>NSC18731</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-chlorodiphenylamine</td>
<td>10 μM</td>
<td></td>
</tr>
<tr>
<td>NSC50453</td>
<td>20 μM</td>
<td>30 μM</td>
</tr>
<tr>
<td>NSC56930</td>
<td>30 μM</td>
<td></td>
</tr>
<tr>
<td>NSC11177</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSC75183</td>
<td>60 μM</td>
<td>60 μM</td>
</tr>
<tr>
<td>Weak binding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSC39744</td>
<td>140 μM</td>
<td>500 μM</td>
</tr>
</tbody>
</table>

(continued on next page)
NSC24035  
\(K_D = 600 \mu M\)  
\(K_{D*} = 1340 \mu M\)

NSC38642  
\(K_D = 270 \mu M\)  
\(K_{D*} = 120 \mu M\)

ChemBridge  
54,451,398  
Weak binding

SHG70  
Weak binding

SHG74  
\(K_D = 210 \mu M\)  
\(K_{D*} = 340 \mu M\)

SHG82  
No binding

SHG102  
\(K_D = 270 \mu M\)  
\(K_{D*} = 340 \mu M\)

SHG116  
Weak binding

SHG123  
No binding

SHG_DPA2  
\(K_D = 130 \mu M\)

SHG_DPA4  
\(K_D = 1200 \mu M\)

SHG_DPA9  
No binding

SHG_DPA1  
\(K_D = 280 \mu M\)

SHG_DPA3  
\(K_D = 1600 \mu M\)

SHG_DPA8  
No binding
the interfacial mode, likely because it does not require any displacement of the switch peptide. The solvent-exposed subsite has some proximity to charged sidechains from cNTnC: Glu63 from helix B and Arg83 from helix D, which form an ion pair, but there are no groups in 3-mDPA that are available for hydrogen bonding to these.

The eight lowest energy structures of the chimerical-drug complex for both interfacial and solvent-exposed binding modes are shown in Figs. 9a and b, respectively. Both drug-bound models were aligned to cChimera without drug (Fig. 9c) and the backbone RMSDs of residues 3–85 were 1.3 Å and 1.2 Å for the interfacial and solvent-exposed binding modes, respectively, similar to the RMSD between the chimera alone and the X-ray structure of the troponin complex (1JEl.pdb). The binding of 3-mDPA does not impart a large-scale structural perturbation to the backbone of cChimera, contrasting with the considerable opening of cNTnC structure needed to accommodate the larger bepridil molecule, particularly its isopropyl group (see Fig. 8c).

3.5. Small molecule binding

We screened many compounds based on DPA for cChimera binding in order to explore its potential as a base structure for drug development (see Table 2). 3-mDPA binds to cChimera through entirely hydrophobic interactions. The choice of compounds to be tested was guided, in part, by the compounds suggested using in silico screening. Based on our structures, it appears that the central nitrogen atom of 3-mDPA does not participate in polar interactions with cChimera. DPA tolerates hydrophobic burial reasonably well because it does not carry appreciable positive charge. The central nitrogen is important for imparting some water solubility to the DPA base structure, but it is replaceable with —O— or —CH2— without a major influence on cChimera binding, even though this changes the central geometry from trigonal planar to tetrahedral.

Strategically placed polar groups are important for the design of highly specific and tightly binding drugs. To date, all charged substituents added to the DPA base structure that we have tested have had an unfavorable effect on binding. Furthermore, attachment of charged amino groups to the DPA backbone via flexible linkers also increased the Kd. The addition of polar but uncharged substituents to the DPA base structure was better tolerated than the addition of charged groups. It is interesting that —F and —Cl have a favorable effect on binding, with 2-chloro-DPA and 3-chloro-DPA having the tightest affinity of all compounds studied to-date. It is possible that van der Waals interactions between chlorine and protein hydrophobic groups are very favorable. Addition of a hydroxyl substituent to DPA slightly decreases affinity, and addition of an amine is less favorable than a hydroxyl. In the immediate vicinity of an aromatic ring, the amine has a slight positive charge (aniline pKa 4.6), while the hydroxyl has a slight negative charge (phenol pKa 10.0). The preference for —OH over —NH may be related more to the lesser partial charge on OH at the acidic pH (6–7) of the NMR samples, rather than any particular charge preference in the drug binding cavity.

One particularly informative series of compounds is that employing single methyl substituents to DPA. 4-mDPA, 3-mDPA, and 2-mDPA all bind more tightly than unsubstituted DPA itself (Kd 60 μM, 30 μM, 15 μM respectively). Much of this is likely due to enhanced hydrophobic interaction to cChimera and decreased water solubility. Nevertheless, the series points towards some important steric effects. The favorable binding of 3-mDPA relative to DPA can be rationalized in terms of the favorable burying of the 3-methyl group in between hydrophobic sidechains of helix B, though this would be partially offset by the loss of interchangeability binding to the deep pocket afforded by the unsubstituted symmetry of DPA. The lowest affinity compound is 4-mDPA, suggesting that a methyl group in the para position is not particularly favorable in any of the three binding subsites highlighted in this study. The best compound of this series is in fact 2-mDPA and not 3-mDPA, perhaps because the 2-methyl-substituted aryl ring is able to bind to any of the three binding subsites. The addition of multiple single atom substituents to the DPA base structure did not appear to increase binding affinity beyond what is observed for a single substituent, though not every possible combination was tested.

Placement of larger substituents on DPA is desirable from a drug development standpoint. Bulky substituents at the para position are not well tolerated, which is not surprising, given that this was the least favorable position for single atom and methyl substituents. Bulky substituents at the meta ring position were better tolerated, but did not improve binding affinity. With the cChimera–3-mDPA structures in hand, it is possible to rationalize why substituents at these positions were not favorable in terms of the three binding sub-sites. Space is very limited in the deep binding pocket, even for single atom substituents. At the switch peptide interface, larger substituents in the meta position cannot fit into the helix B groove like the single methyl group of 3-mDPA, and substituents at the other meta position on the ring would further displace the switch peptide.

4. Conclusion

Our solution NMR structures of cChimera bound to 3-mDPA show that DPA-based compounds bind well to cardiac troponin compared to much larger compounds like bepridil. Binding to the DPA base structure is less perturbing to the troponin C1 domain, requiring only minimal re-positioning of sidechains (Met80 in cTnC, Ile148 in cTnl). Previous cTnC-cTnI-small molecule structures show more extensive opening of cNTnC and more extensive displacement of the cTnl switch peptide, creating a large drug binding cavity. The cavity in the current study is much smaller, explaining the restrictive pattern of binding seen in our collection of DPA-like molecules. This defined binding site will facilitate in silico screening of potential high affinity compounds.

The flexibility of cNTnC itself and the adaptability of its interface with the cTnl switch region explains why the cNTnC-cTnl complex is able to bind to many structurally unrelated small molecules, albeit with low affinity. Preservation of the preferred native conformation of the troponin complex appears to be critical in designing high affinity cardiac troponin modulators.

Disclosures

The authors declare that there are no potential conflicts of interest to disclose.

Acknowledgments

This study was supported by grants from Heart and Stroke Foundation of Canada (B.D.S., G–14–0005884) and Canadian Institutes of Health Research (CIHR) (B.D.S., 37769). The authors also acknowledge support from the Hwang Professional Corporation and startup funds (to P.M.H.) from the University of Alberta Faculty of Medicine & Dentistry and the Department of Medicine. The authors would like to thank Dr. J. Andrew McCammon for helpful discussions.

Appendix A. Supplementary data

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.yjmcc.2016.10.016.

References

S. Szilágyi, P. Pollesello, J. Levijoki, P. Kaheinen, H. Haikala, I. Édes, et al., The effects of
T. Sorsa, P. Pollesello, P. Permi, T. Drakenberg, I. Kilpeläinen, Interaction of
E. Grossini, C. Molinari, P.P. Caimmi, F. Uberti, G. Vacca, Levosimendan induces NO
A. Rezvanpour, J.M. Phillips, G.S. Shaw, Design of high-affinity S100-target hybrid
F. Delaglio, S. Grzesiek, G. Vuister, G. Zhu, J. Pfeifer, A. Bax, NMRPipe: a multidimen-
B.A. Johnson, R.A. Blevins, NMR view: a computer program for the visualization and
Y. Shen, F. Delaglio, G. Cornilescu, A. Talos+: a hybrid method for predicting protein
M.B. Dohna-Halpern, A Simple Method To Predict Protein Flexibility Using Secondary
J.P. Linge, M. Habeck, M. Nilges, ARIA2: automated NOE assignment and data integra-
Y. Li, M.L. Love, J.A. Putkey, C. Cohen, Bepridil opens the regulatory N-terminal lobe
A.R. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren,
S. Lindert, W. Zhu, Y.-L. Liu, R. Pang, E. Oldfield, J.A. McCammon, Farnesyl diphos-
P. Mercier, C.N. Allen, O. Fiset, C.H.J. Ramos, P. Lague, et al., Is there na-
144
143